Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Kidney Int. 2012 May 23;82(6):643–651. doi: 10.1038/ki.2012.170

Figure 6.

Figure 6

Angiotensin (Ang) II treatment increased plasminogen activator inhibitor (Pai)-1 mRNA levels in cardiac (A), renal (B), and aortic (C) tissue in wild-type (WT) mice. Spironolactone (SPL) or genetic aldosterone synthase deficiency (As-/-) prevented this increase within the heart and aorta, and attenuated the effect within the kidney. *P<0.05 vs. WT-vehicle; †P<0.05 vs. WT-Ang II; ‡P<0.05 vs. As-/--Vehicle-SPL.